Deep-dive AI research reports on individual stocks, powered by our proprietary signals. Every report carries a direction (Bullish or Bearish) and a conviction level(Strong or Speculative). We track stock performance since each report's publication date — because we believe great analysis should be held accountable.

AllAAOIABUSABVXACADACRVADMAAGIOALMSALMUALTSAPGEARTVASXAUPHAVAVAVPTAXTIBCRXCAICAKECEGCELCCEPCGONCIENCNCCOGTCRCLCTMXCTRIDKNGDUOLFLUTGCTGLWGOOGGPCRHALOHCAHIMSHOODHWMIDYAIRENIVVDKALAKALVKRYSLENZLEVILITELQDALRMRLULULUNRMDGLMESOMIRMMOHMPWRMTCHMUMVSTNBISNKENRIXNUENVAXNXPIOKUROLMAONCONTOORKAOSCRPDFSPHATPOETPRLDPYGRBLXRDDTRIGLRKLBSGHCSPRYSRPTTARSTBPHTHTRVITSHATTMIUNHVEONVORWVEXFORZBIOZLABZYME
Alumis's stock surge is a cynical liquidity event. Insiders bought low, hyped Phase 3 data, then sold shares high in a $345M offering. Despite cash, the drug faces a crowded market and massive cash burn.

The TYK2 Trojan Horse: Exposing the Engineered Squeeze in Alumis Inc. (ALMS)

2026-04-04BearishStrongChange from report: -68.8%1M: +15.1%3M: +24.3%

Alumis's stock surge is a cynical liquidity event. Insiders bought low, hyped Phase 3 data, then sold shares high in a $345M offering. Despite cash, the drug faces a crowded market and massive cash burn.